- Home
- GENI vs FOLD Comparison
GENI vs FOLD Comparison
Compare GENI & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENI
- FOLD
- Stock Information
- Founded
- GENI 2016
- FOLD 2002
- Country
- GENI United Kingdom
- FOLD United States
- Employees
- GENI N/A
- FOLD N/A
- Industry
- GENI Services-Misc. Amusement & Recreation
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- GENI Consumer Discretionary
- FOLD Health Care
- Exchange
- GENI Nasdaq
- FOLD Nasdaq
- Market Cap
- GENI 3.0B
- FOLD 2.5B
- IPO Year
- GENI N/A
- FOLD 2007
- Fundamental
- Price
- GENI $12.48
- FOLD $8.02
- Analyst Decision
- GENI Strong Buy
- FOLD Strong Buy
- Analyst Count
- GENI 16
- FOLD 10
- Target Price
- GENI $13.75
- FOLD $26.89
- AVG Volume (30 Days)
- GENI 4.9M
- FOLD 3.7M
- Earning Date
- GENI 08-06-2025
- FOLD 11-05-2025
- Dividend Yield
- GENI N/A
- FOLD N/A
- EPS Growth
- GENI N/A
- FOLD N/A
- EPS
- GENI N/A
- FOLD N/A
- Revenue
- GENI $558,439,000.00
- FOLD $571,160,000.00
- Revenue This Year
- GENI $27.93
- FOLD $20.98
- Revenue Next Year
- GENI $16.92
- FOLD $20.74
- P/E Ratio
- GENI N/A
- FOLD N/A
- Revenue Growth
- GENI 25.76
- FOLD 25.35
- 52 Week Low
- GENI $6.72
- FOLD $5.51
- 52 Week High
- GENI $13.73
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- GENI 49.54
- FOLD 68.58
- Support Level
- GENI $12.31
- FOLD $7.79
- Resistance Level
- GENI $13.73
- FOLD $8.11
- Average True Range (ATR)
- GENI 0.41
- FOLD 0.22
- MACD
- GENI -0.13
- FOLD -0.02
- Stochastic Oscillator
- GENI 14.40
- FOLD 73.42
About GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.